Xgeva Denosumab Injection Vial 120 mg/1.7 mL (70 mg/mL) Single-Dose Vial by Amgen (RX) ** Requires Refrigeration

Xgeva® is a prescription medication containing the active ingredient denosumab. It is supplied in a single-dose vial, delivering 120 mg of denosumab in a 1.7 mL solution (70 mg/mL). Xgeva® is manufactured and distributed by Amgen, a leader in biotechnology.

Denosumab works by inhibiting the RANK ligand (RANKL), a protein essential for the formation, function, and survival of osteoclasts, the cells that break down bone. By inhibiting RANKL, Xgeva® helps to reduce bone resorption and maintain bone strength, thus preventing fractures and other bone-related complications.

Indications:

Xgeva® is primarily used to prevent skeletal-related events in patients with bone metastases from solid tumors. It is also used for the treatment of giant cell tumor of bone that is unresectable or when surgical resection is likely to result in severe morbidity. Additionally, Xgeva® is indicated for the treatment of hypercalcemia of malignancy that is refractory to bisphosphonate therapy.

Administration and Dosage:

Xgeva® is administered via subcutaneous injection. The recommended dosage for:

• Prevention of skeletal-related events in patients with bone metastases from solid tumors: 120 mg once every 4 weeks.
  
• Treatment of giant cell tumor of bone: 120 mg once every 4 weeks, with additional 120 mg doses on days 8 and 15 of the first month of therapy.
  
• Treatment of hypercalcemia of malignancy: 120 mg once every 4 weeks.

Storage and Handling:

• Store Xgeva® in a refrigerator at 2°C to 8°C (36°F to 46°F) in its original carton to protect from light.
  
• Do not freeze.
  
• Do not shake the vial.
  
• Prior to administration, Xgeva® may be kept at room temperature (up to 25°C or 77°F) for a maximum of 14 days.

Side Effects:

Common side effects include fatigue, weakness, hypophosphatemia, nausea, and diarrhea. Serious potential side effects include osteonecrosis of the jaw, atypical femoral fractures, and severe symptomatic hypocalcemia, particularly in patients with risk factors such as reduced renal function.

Warnings and Precautions:

• Monitor calcium levels prior to and during treatment.
  
• Ensure sufficient intake of calcium and vitamin D.
  
• Use with caution in patients with pre-existing hypocalcemia.
  
• Regular dental check-ups and good oral hygiene are recommended to reduce the risk of osteonecrosis of the jaw.

Patient Counseling Information:

Patients should be informed about the purpose of the treatment, potential side effects, and the importance of maintaining regular check-ups. They should be advised to report any symptoms of hypocalcemia (e.g., muscle spasms, cramps, tingling) and to practice good oral hygiene to reduce the risk of jaw problems. 

Xgeva® is a critical treatment option for managing bone complications associated with cancer and certain bone tumors. Proper administration and patient adherence to guidelines are essential for maximizing the therapeutic benefits and minimizing risks.